Claims for Patent: 11,744,802
✉ Email this page to a colleague
Summary for Patent: 11,744,802
| Title: | Therapeutic compositions for treatment of human immunodeficiency virus |
| Abstract: | A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Benjamin Micah Collman, Lei Hong, Joanna M. Koziara |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US17/738,803 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,744,802 |
| Patent Claims: |
1. A tablet comprising 50 mg of the compound of Formula I: or a pharmaceutically acceptable salt thereof, 25 mg tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and 200 mg emtricitabine or a pharmaceutically acceptable salt thereof. 2. The tablet of claim 1, wherein the tablet comprises 50 mg of the compound of Formula I as a pharmaceutically acceptable salt thereof. 3. The tablet of claim 1, wherein the tablet comprises 25 mg tenofovir alafenamide as a pharmaceutically acceptable salt thereof. 4. The tablet of claim 1, wherein the tablet comprises 50 mg of the compound of Formula I as a pharmaceutically acceptable salt thereof, 25 mg tenofovir alafenamide as a pharmaceutically acceptable salt thereof, and 200 mg emtricitabine. 5. The tablet of claim 1, wherein the tablet comprises 52 mg of the sodium salt of the compound of Formula I. 6. The tablet of claim 1, wherein the tablet comprises 25 mg tenofovir alafenamide as tenofovir alafenamide fumarate. 7. The tablet of claim 1, wherein the tablet comprises 28 mg tenofovir alafenamide hemifumarate. 8. The tablet of claim 1, wherein the tablet comprises 52 mg of the sodium salt of the compound of Formula I, 28 mg tenofovir alafenamide hemifumarate, and 200 mg emtricitabine. 9. The tablet of claim 1, wherein the tablet has a total weight of less than 1000 mg. 10. The tablet of claim 9, wherein the tablet has a total weight of less than 800 mg. 11. The tablet of claim 10, wherein the tablet has a total weight of less than 730 mg. 12. The tablet of claim 1, wherein the tablet contains less than 15% of the compound of Formula I or a pharmaceutically acceptable salt thereof. 13. The tablet of claim 1, wherein the tablet contains less than 11% of the compound of Formula I or a pharmaceutically acceptable salt thereof. |
